“Neutropenia - Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 30+ pipeline drugs in Neutropenia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered • Global coverage
Neutropenia: Overview Neutropenia is a blood condition characterized by low levels of neutrophils, which are white blood cells that protect your body from infections. There are four types of neutropenia: Congenital neutropenia, cyclic neutropenia, autoimmune neutropenia, Idiopathic neutropenia. Neutropenia symptoms can range from mild to severe. The lower the level of neutrophils, the more intense the symptoms. Typical symptoms include: fever, pneumonia, sinus infections, otitis media (ear infection), gingivitis (gum inflammation), omphalitis (navel infection) and skin abscesses. Severe congenital neutropenia can have serious symptoms. The symptoms often include bacterial infections. These infections can grow on the skin and in the digestive and respiratory systems. The symptoms of cyclic neutropenia recur in 3-week cycles. Infections can increase when neutrophil levels fall. Neutropenia can be triggered by: chemotherapy, radiation therapy, the use of certain drugs.
Report Highlights • The companies and academics are working to assess challenges and seek opportunities that could influence Neutropenia R&D. The therapies under development are focused on novel approaches for Neutropenia.
Neutropenia Emerging Drugs Chapters This segment of the Neutropenia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Neutropenia Emerging Drugs • Plinabulin: BeyondSpring Pharmaceuticals
Plinabulin, BeyondSpring’s lead asset, is a selective immune-modulating microtubule-binding agent (SIMBA). A global Phase 3 clinical trial in CIN (PROTECTIVE-2) with plinabulin in combination with pegfilgrastim versus pegfilgrastim alone has been completed and is the basis for an NDA filing in the U.S. and China for the prevention of CIN. In this trial, plinabulin reduced the “neutropenia vulnerability gap” associated with G-CSF therapy alone.
In March, 2021, BeyondSpring announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) and the China National Medical Products Administration (NMPA) for use of plinabulin in combination with granulocyte colony-stimulating factor (G-CSF) for the prevention of chemotherapy-induced neutropenia (CIN).
• Romyelocel-L: Cellerant Therapeutics
Romyelocel-L, a composition of human myeloid progenitor cells, can be administered to provide a source of mature neutrophils and provide transient innate immunity until the patient’s own immune system recovers.
Romyelocel-L is being developed to prevent bacterial and fungal infections in patients with prolonged neutropenia. Romyelocel-L has been evaluated in three clinical trials to date. In a randomized, controlled Phase 2 trial (NCT02282215), romyelocel-L significantly reduced infections and days in hospital. Romyelocel-L has shown an acceptable safety profile in the three clinical trials, with a total of 151 subjects aged 12 years and above exposed to romyelocel-L.
Further product details are provided in the report……..
Neutropenia: Therapeutic Assessment This segment of the report provides insights about the different Neutropenia drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players working on Neutropenia
There are approx. 20+ key companies which are developing the Neutropenia. The companies which have their Neutropenia drug candidates in the most advanced stage, i.e. Preregistration include, BeyondSpring Pharmaceuticals.
This report covers around 30+ products under different phases of clinical development like
• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Neutropenia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Molecule Type
Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Small molecule
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Neutropenia: Pipeline Development Activities The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Neutropenia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Neutropenia drugs.
Current Scenario and Emerging Therapies: • How many companies are developing Neutropenia drugs?
• How many Neutropenia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Neutropenia?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Neutropenia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Neutropenia and their status?
• What are the key designations that have been granted to the emerging drugs?
“Axial spondyloarthritis - Pipeline Insight, 2021,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Axial spondyloarthritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route...
The Formulation Development Outsourcing market was valued at approximately USD 8,055 million in 2020 and is expected to witness a revenue of USD 12,650 million in 2026, with a CAGR of 7.2% over the forecast period. The rapidly evolving threat of COVID-19 is impacting lives, communities, businesses, and industries around the world. The...
529 pages •
By Global Industry Analysts
• Apr 2021
- Global Drug Discovery Technologies Market to Reach $74.3 Billion by 2027
- Amid the COVID-19 crisis, the global market for Drug Discovery Technologies estimated at US$44.2 Billion in the year 2020, is projected to reach a revised size of US$74.3 Billion by 2027, growing at aCAGR of 7.7% over the period...
The global custom antibody market is projected to reach USD 652 million by 2026 from USD 393 million in 2021, at a CAGR of 10.6% during the forecast period.The increasing demand for protein therapeutics is expected to drive the custom antibody market in the coming years. On the other hand, the need for significant capital investments and long...
“Protein 50S ribosomal subunit inhibitors– Pipeline Insight, 2021,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Protein 50S ribosomal subunit inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment...
Readers of one of the analyst’s media partners were invited to participate in an online survey in September 2020 that centered on the state of their laboratories in 2020 and their expectations for 2021.The analyst has conducted similar studies among the same targeted respondents since 2012.
Where applicable, the study presents year-over-year...
“Sialorrhoea – Pipeline Insight, 2021,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Sialorrhoea pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule...
Interleukin 1 (IL1) - Drugs in Development, 2021 Summary According to the recently published report ’Interleukin 1 - Drugs in Development, 2021’; Interleukin 1 (IL1) pipeline Target constitutes close to 36 molecules. Out of which approximately 35 molecules are developed by companies and remaining...
The analyst presents post-COVID-19 growth opportunities and strategic imperatives in the contract research organization (CRO) market, covering the market’s maturity, key participants, competitive landscape, and recent mergers and acquisitions. The study highlights key growth drivers and restraints, identifies initiatives by major global CROs,...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.